Kin-Ming Lo

4.5k total citations · 3 hit papers
43 papers, 3.5k citations indexed

About

Kin-Ming Lo is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Kin-Ming Lo has authored 43 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 18 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Immunology. Recurrent topics in Kin-Ming Lo's work include Monoclonal and Polyclonal Antibodies Research (18 papers), Glycosylation and Glycoproteins Research (11 papers) and Angiogenesis and VEGF in Cancer (9 papers). Kin-Ming Lo is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), Glycosylation and Glycoproteins Research (11 papers) and Angiogenesis and VEGF in Cancer (9 papers). Kin-Ming Lo collaborates with scholars based in United States, Italy and Germany. Kin-Ming Lo's co-authors include Kashi Javaherian, Judah Folkman, Stephen D. Gillies, Douglas Hanahan, Gabriele Bergers, Yan Lan, Khashayar Vakili, Karen S. Moulton, David Zurakowski and Catherine Butterfield and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Kin-Ming Lo

42 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice

1999 811 citations Gabriele Bergers, Kashi Javaherian et al. Science profile →
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis

2003 538 citations Kin-Ming Lo, Stephen D. Gillies et al. Proceedings of the National Academy of Sciences profile →
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

2018 405 citations Yan Lan, Dong Zhang et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kin-Ming Lo United States	27	1.8k	1.4k	1.1k	789	688	43	3.5k
P. Charles Lin United States	27	1.9k 1.0×	1.6k 1.2×	1.6k 1.5×	430 0.5×	837 1.2×	35	4.1k
Bahija Jallal United States	47	2.6k 1.4×	1.3k 1.0×	2.0k 1.9×	707 0.9×	634 0.9×	86	5.5k
Marcel Spaargaren Netherlands	43	3.1k 1.7×	1.4k 1.0×	1.2k 1.1×	224 0.3×	505 0.7×	98	5.8k
Yoshinori Ino Japan	34	1.7k 0.9×	1.3k 1.0×	660 0.6×	175 0.2×	517 0.8×	63	3.5k
Sonja Loges Germany	35	2.7k 1.5×	1.9k 1.4×	926 0.9×	260 0.3×	1.4k 2.1×	98	5.0k
Ruth Ganß Australia	32	1.9k 1.0×	1.9k 1.4×	1.9k 1.8×	177 0.2×	1.1k 1.5×	58	4.5k
M. OʼReilly United States	14	3.7k 2.1×	1.9k 1.4×	719 0.7×	460 0.6×	2.2k 3.2×	30	6.0k
Patrizia Casalini Italy	38	3.0k 1.7×	1.7k 1.2×	1.0k 1.0×	570 0.7×	2.5k 3.7×	79	5.3k
Oreste Segatto United States	31	1.9k 1.1×	2.0k 1.4×	425 0.4×	1.2k 1.5×	357 0.5×	55	3.4k
Carlton R. Cooper United States	20	1.0k 0.6×	1.4k 1.0×	553 0.5×	193 0.2×	415 0.6×	40	2.7k

Countries citing papers authored by Kin-Ming Lo

Since Specialization

Citations

This map shows the geographic impact of Kin-Ming Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kin-Ming Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kin-Ming Lo more than expected).

Fields of papers citing papers by Kin-Ming Lo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kin-Ming Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kin-Ming Lo. The network helps show where Kin-Ming Lo may publish in the future.

Co-authorship network of co-authors of Kin-Ming Lo

This figure shows the co-authorship network connecting the top 25 collaborators of Kin-Ming Lo. A scholar is included among the top collaborators of Kin-Ming Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kin-Ming Lo. Kin-Ming Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Feng, Hong Wang, Tsz-Lun Yeung, et al.. (2021). 609 Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway. SHILAP Revista de lepidopterología. A639–A639. 1 indexed citations

Lan, Yan, Dong Zhang, Chunxiao Xu, et al.. (2018). Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Science Translational Medicine. 10(424). 405 indexed citations breakdown →

Xu, Chunxiao, Yanping Zhang, Alex Rolfe, et al.. (2017). Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clinical Cancer Research. 23(19). 5869–5880. 58 indexed citations

Strauss, James, Jeffrey Schlom, Ravi A. Madan, et al.. (2016). A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors. European Journal of Cancer. 69. S103–S104. 2 indexed citations

Waight, Jeremy D., Shinji Takai, Bo Marelli, et al.. (2014). Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans. The Journal of Immunology. 194(3). 878–882. 47 indexed citations

Gillies, Stephen D., Yan Lan, Thore Hettmann, et al.. (2011). A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity. Clinical Cancer Research. 17(11). 3673–3685. 77 indexed citations

Davis, Jonathan H., Christel Aperlo, Yue Li, et al.. (2010). SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Protein Engineering Design and Selection. 23(4). 195–202. 153 indexed citations

Sjin, Robert Tjin Tham, et al.. (2007). Improved pharmacokinetics and efficacy of endostatin by fusion with IgG Fc domain. 67. 4598–4598. 1 indexed citations

Gillies, Stephen D., Yan Lan, Steven A. Williams, et al.. (2005). An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood. 105(10). 3972–3978. 77 indexed citations

10.

Lo, Kin-Ming, Jinyang Zhang, Yaping Sun, et al.. (2005). Engineering a pharmacologically superior form of leptin for the treatment of obesity. Protein Engineering Design and Selection. 18(1). 1–10. 27 indexed citations

11.

Way, Jeffrey C., Scott Lauder, Beatrice Brunkhorst, et al.. (2005). Improvement of Fc–erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Engineering Design and Selection. 18(3). 111–118. 28 indexed citations

12.

Jones, Tim D., B.J. Smith, Charles T. Heise, et al.. (2004). The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research. 24(9). 560–572. 32 indexed citations

13.

Lo, Kin-Ming, Lan Yan, Scott Lauder, et al.. (2004). HuBC1-IL12: A very potent immunocytokine which targets the oncofetal fibronectin in the extracellular matrix of tumor vasculature. Cancer Research. 64. 1082–1082. 1 indexed citations

14.

Gillies, Stephen D., Lan Yan, Scott Lauder, et al.. (2004). Engineering of an IL-2 immunocytokine with very low toxicity that retains potent anti-tumor activity in immune competent and immune deficient mouse tumor models. Cancer Research. 64. 151–152. 2 indexed citations

15.

Gillies, Stephen D., et al.. (2002). Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunology Immunotherapy. 51(8). 449–460. 60 indexed citations

16.

Gillies, Stephen D., Lan Yan, Kin-Ming Lo, Michael Super, & John S. Wesolowski. (1999). Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.. PubMed. 59(9). 2159–66. 37 indexed citations

17.

Bergers, Gabriele, Kashi Javaherian, Kin-Ming Lo, Judah Folkman, & Douglas Hanahan. (1999). Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice. Science. 284(5415). 808–812. 811 indexed citations breakdown →

18.

Lo, Kin-Ming, et al.. (1998). High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Engineering Design and Selection. 11(6). 495–500. 69 indexed citations

19.

Gillies, Stephen D., Edward B. Reilly, Kin-Ming Lo, & R. Reisfeld. (1992). Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.. Proceedings of the National Academy of Sciences. 89(4). 1428–1432. 159 indexed citations

20.

Jones, Simon S., et al.. (1985). Activation of Ha- ras p21 by Substitution, Deletion, and Insertion Mutations. Molecular and Cellular Biology. 5(8). 1809–1813. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact